Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine When do we choose semaglotide and when does terzipatide? EASO has just announced that it will update its algorithm with evidence until November 2025 Warning: It depends on the clinical goal. CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Zepbound beats CagriSema in head to head trial : r Zepbound Novo Nordisk launches trial of pipeline drug CagriSema versus newly approved Zepbound Clinical Trials Arena